Geoff Porges News
-
Gilead Sciences Inc., after paying $10.8 billion for the developer of an experimental hepatitis C drug, will soon give investors a better sense of whether its largest-deal ever is going to pay off.
-
At Fred Poordad’s bustling hepatitis C clinic in the heart of Los Angeles, one in every five patients receives no treatment. They are waiting for a wave of new drugs, expected in the next 18 months, that may boost their chance at a cure by as much as 10-fold.
-
Medivation Inc., a company that acquires early-development drugs, more than doubled after its prostate cancer medicine proved so effective that it halted a clinical trial and gave the medicine to all participants.
-
Genzyme Corp. , the world’s largest maker of drugs for rare genetic diseases, rebuffed Sanofi- Aventis SA ’s takeover approach last week, two people with knowledge of the matter said today.
-
Gilead Sciences Inc., the world’s largest maker of HIV medicines, agreed to buy Pharmasset Inc. for about $11 billion, betting that its experimental hepatitis C treatments will lead the next generation of therapies in a market that may reach $20 billion by 2020.
-
Gilead Sciences Inc. declined the most in 18 months in Nasdaq trading after cutting its revenue forecast and reporting sales of top products that missed analysts’ estimates.
-
Gilead Sciences Inc., the world’s largest maker of AIDS drugs, lowered its 2010 sales forecast, saying the U.S. health-care overhaul passed last month will reduce revenue by $200 million.
-
Sanofi-Aventis SA Chief Executive Officer Chris Viehbacher has support from his board of directors to offer as much as $70 a share for Genzyme Corp. , or about $18.7 billion, said three people with knowledge of the situation.
-
Investors should buy bullish Genzyme Corp. options to profit from a possible public bid from Sanofi- Aventis SA for the world’s largest maker of drugs for rare genetic diseases, MKM Partners LP said.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page